Systemic corticosteroid therapy augments ex vivo release of sCD163 by peripheral blood monocytes of asthmatic patients
| العنوان: | Systemic corticosteroid therapy augments ex vivo release of sCD163 by peripheral blood monocytes of asthmatic patients |
|---|---|
| المؤلفون: | Pawel Bernatowicz, Krzysztof Kowal, Paweł Golec, Pawel Bielecki |
| المصدر: | Advances in Dermatology and Allergology, Vol 37, Iss 1, Pp 61-65 (2020) Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii |
| بيانات النشر: | Termedia Publishing House, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Cell, Dermatology, cd163, Peripheral blood mononuclear cell, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Immunology and Allergy, Asthmatic patient, Asthma, Original Paper, business.industry, asthma, medicine.disease, RC31-1245, In vitro, medicine.anatomical_structure, Endocrinology, Corticosteroid therapy, induced sputum, RL1-803, inhaled corticosteroids, business, CD163, Ex vivo |
| الوصف: | Introduction The CD163 is exclusively expressed by mononuclear phagocytes as a transmembrane protein, which synthesis is regulated by anti- and pro-inflammatory signals. After shedding from the cell surface it exists in body fluids as a soluble protein (sCD163) which exerts anti-inflammatory effects. Aim To evaluate serum concentration and ex vivo production of sCD163 by peripheral blood mononuclear cells (PBMC) in asthmatic patients treated with inhaled (ICS) or oral corticosteroids (OCS). Material and methods The study was performed on 35 allergic asthma patients (AAs) including 15 treated with ICS (ICS-AAs), 10 with OCS (OCS-AAs), 10 during asthma exacerbation (EX-AAs) before OCS had been started and 13 non-atopic healthy subjects (HCs) as a control group. PBMC were cultured in vitro for up to 144 h. The concentration of sCD163 in serum and the culture supernatants was evaluated with ELISA. Results The greatest serum sCD163 concentration was demonstrated in EX-AAs, which was significantly greater than that in other studied subgroups. The concentration of sCD163 in PBMC culture supernatants was greater in AAs than in HCs (p = 0.006). Among individual asthma subgroups the greatest concentration of sCD163 was demonstrated in PBMC culture supernatants of OCS-AAs, which was significantly greater than in ICS-AAs (p < 0.001) and EX-AAs (p < 0.001), both being significantly greater than in HCs (p < 0.001). Conclusions In AAs, enhanced capability of PBMCs to release sCD163 may be at least partially responsible for the anti-inflammatory effects of systemic corticosteroid therapy. |
| اللغة: | English |
| تدمد: | 2299-0046 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc46b377c5ecc46986f55f036c595e01Test https://www.termedia.pl/Systemic-corticosteroid-therapy-augments-ex-vivo-release-r-nof-sCD163-by-peripheral-blood-monocytes-of-asthmatic-r-npatients,7,40012,1,1.htmlTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....dc46b377c5ecc46986f55f036c595e01 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22990046 |
|---|